Press Releases

Lilly Initiates Phase 3 Trial of LY-CoV555 for Prevention of COVID-19 at Long-Term Care Facilities in Partnership with the National Institute of Allergy and Infectious Diseases (NIAID)

August 3, 2020

Tags |  Product

- More than 40 percent of coronavirus deaths in the U.S. linked to long-term care facilities; urgent need for therapeutic strategies to prevent COVID-19 in this vulnerable population   - First-of-its-kind study will enroll up to 2,400 residents and staff at long-term care facilities; will utilize

Jardiance® meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in phase III trial in adults with and without diabetes

July 30, 2020

Tags |  Product

- Jardiance (empagliflozin) significantly reduced the risk of cardiovascular death or hospitalization for heart failure versus placebo in the EMPEROR-Reduced heart failure trial. The study evaluated adults with heart failure with reduced ejection fraction   - Treatment of heart failure is an

Lilly's P-tau217 Blood Test Shows High Accuracy in Diagnosis of Alzheimer's Disease in Data Published in JAMA

July 28, 2020

Tags |  Product

New Alzheimer's disease blood test could enable early diagnosis and advance understanding of how disease impacts those living with it INDIANAPOLIS , July 28, 2020 /PRNewswire/ -- A new study on Lilly 's blood test for Alzheimer's disease (AD), P-tau217 (phosphorylated tau at threonine-217), was

Data from Lilly at Alzheimer's Association International Conference 2020® (AAIC® 2020) to Showcase Clinical Advances in Alzheimer's Research

July 21, 2020

Tags |  Product

Highlights include data that advance the understanding of Alzheimer's disease across the spectrum including early and accurate detection, diagnosis and treatment INDIANAPOLIS , July 21, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today announced that new results from 17 research studies

Lilly's Mirikizumab Superior to Cosentyx® (secukinumab) in a Phase 3 Study for Patients with Moderate to Severe Plaque Psoriasis

July 17, 2020

Tags |  Product

- Mirikizumab met the primary and all key secondary endpoints versus placebo at Week 16 and all key secondary endpoints versus Cosentyx® (secukinumab) at Week 16 and Week 52, including superiority in skin clearance at Week 52   - Lilly will submit data from OASIS-1 and 2 to regulatory authorities

Lilly launches program about what people with diabetes should "Know Before the Low™"

June 24, 2020

Tags |  Product

Singer/songwriter Crystal Bowersox kicks off the educational initiative by encouraging people to educate their support network and develop a plan for low blood sugar and very low blood sugar emergencies INDIANAPOLIS , June 24, 2020 /PRNewswire/ -- About 34 million Americans live with diabetes, and

Full results from EMPERIAL exercise ability trials presented

June 19, 2020

Tags |  Product

RIDGEFIELD, Conn. and INDIANAPOLIS, June 19, 2020 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced full results from the EMPERIAL-Reduced and EMPERIAL-Preserved trials related to exercise ability and symptom improvement with Jardiance ® (empagliflozin) in

Emgality® Demonstrates Reduction in Frequency, Duration, and Pain Severity in Patients with Episodic and Chronic Migraine

June 17, 2020

Tags |  Product

INDIANAPOLIS , June 17, 2020 /PRNewswire/ -- Emgality ® (galcanezumab-gnlm) reduces total pain burden in a recent analysis of patients with episodic and chronic migraine. Total pain burden is a patient-centric measure that combines the monthly frequency, duration, and pain severity of migraine.

Lilly's OVERCOME Study Reveals Less than 30 Percent of People Living with Migraine Take Recommended Prescription Medications

June 16, 2020

Tags |  Product

- Data showed approximately 1 in 3 people diagnosed with migraine take a recommended acute prescription medication for a migraine attack, while less than 1 in 5 who suffer frequent migraine attacks take a recommended preventive prescription medication   - OVERCOME (Observational Survey of the

Verzenio® (abemaciclib) Significantly Reduced the Risk of Cancer Returning in People with High Risk HR+, HER2- Early Breast Cancer

June 16, 2020

Tags |  Product

monarchE demonstrates positive results in Phase 3 study of 5,637 people whose early breast cancer is at a high risk of recurrence   Verzenio given with standard endocrine therapy showed improvement compared to standard endocrine therapy alone   Verzenio is the only CDK4 & 6 inhibitor to demonstrate